The various classes and subclasses of immunoglobulin that make up the humoral immune repertoire are primarily defined by their heavy chain constant domain sequences. Immunoglobulin subtypes differ in their underlying biologic regulation, distribution in the body, and in their interaction with receptors on the various effector cells of the immune system [1]. Class-switch gene rearrangement of the constant regions determines which immunoglobulin subtypes are produced in response to a particular immune challenge. Class-switching is regulated in part by the particular cytokines produced in response to the type and location of the immune challenge. A relatively simple example is the production of immunoglobulin E, an antibody without subclasses produced in response to various T helper 2 (Th2) cytokines, which ultimately interacts with IgE receptors on mast cells, basophils, and eosinophils to initiate release of inflammatory mediators associated with an allergic response [2].
Introduction
The various classes and subclasses of immunoglobulin that make up the humoral immune repertoire are primarily defined by their heavy chain constant domain sequences. Immunoglobulin subtypes differ in their underlying biologic regulation, distribution in the body, and in their interaction with receptors on the various effector cells of the immune system [1] . Class-switch gene rearrangement of the constant regions determines which immunoglobulin subtypes are produced in response to a particular immune challenge. Class-switching is regulated in part by the particular cytokines produced in response to the type and location of the immune challenge. A relatively simple example is the production of immunoglobulin E, an antibody without subclasses produced in response to various T helper 2 (Th2) cytokines, which ultimately interacts with IgE receptors on mast cells, basophils, and eosinophils to initiate release of inflammatory mediators associated with an allergic response [2] .
In contrast, the IgG class is more complex in structure and biology. There are four subclasses of IgG antibodies, numbered 1 through 4 in the order of their discovery and serum concentration. Properties of individual subtypes are summarized in Table 1 [3 -5] . The most abundant subclass, IgG1, is present in serum in the range of 5-11 mg/ml [3] , whereas the least abundant subclass, IgG4, is present at mean concentrations of 0.35-0.51 mg/ml [6 ] . Unlike the other IgG subclasses, the concentration of IgG4 varies greatly among healthy people. IgG4 levels generally range from less than 10 mg/ml to 1.4 mg/ml, with levels over 2 mg/ml noted in a few individuals and levels generally higher in men and older individuals [3, 6 ,7] . Although it is not known what governs this variation in abundance of serum IgG4 between individuals, we have noted little fluctuation in levels over time in a cohort of multiple sclerosis (MS) patients, suggesting tight regulation of IgG4 production and turnover (Biogen Idec, unpublished data). We speculate for now that this tight regulation of IgG4 levels over time is not specific to MS and likely occurs in disease-free individuals, although Purpose of review Recent descriptions of the group of clinical disorders collectively defined as IgG4-related systemic disease (IgG4-RSD) have prompted this review of the unique biology of the IgG4 antibody. This article will discuss IgG4 structure and function, the unique phenomenon of half-antibody exchange, and the implications of IgG4 biology for its proposed role in immunologic diseases.
Recent findings
IgG4 antibodies have unique structural and functional properties and undergo 'halfantibody exchange' in vivo, resulting in recombined antibodies composed of two different binding specificities. The production of IgG4 antibodies appears to be driven in part by T helper 2 (Th2) cytokines that mediate allergic responses and IgE production. Although serum IgG4 levels in healthy individuals vary significantly, data from multiple sclerosis (MS) patients suggest tight regulation of individual IgG4 levels over time. IgG4-RSD represents a diverse group of clinical disorders unified by elevated IgG4 levels and specific histopathologic findings. A key unanswered question is whether IgG4, a relatively weak activator of effector cells, is pathogenic in these disorders.
Summary
IgG4 is a unique antibody biologically and structurally. Increased understanding of its precise role in the clinical syndromes that comprise IgG4-RSD may ultimately elucidate the underlying pathogenesis. this hypothesis warrants verification. As will be discussed elsewhere, tight regulation of IgG4 levels is lost in IgG4-RSD, with elevated antibody levels paralleling disease activity.
The IgG4 subclass was distinguished early on from the other IgG subclasses, as it exhibits negligible binding to the C1q protein complex and is unable to activate the classical complement pathway. It was also found that IgG4 has much reduced binding to the low-affinity Fcgamma receptors (FcgRIIa and FcgRIIIa) and a 10-fold reduction in binding to the high-affinity FcgRI, compared with IgG1 [3]. This reduction in effector binding has led to the selection of the IgG4 constant domain for use in recombinant antibodies for clinical development wherein effector function is either unnecessary or is potentially undesirable. At least eight IgG4 monoclonal antibodies (mAbs) have been reported to be in various stages of clinical development or are marketed therapeutics (Table 2) (ClinicalTrials.gov (http://clinical trials.gov) [8] [9] [10] [11] [12] [13] [14] . Therapeutics that have shown clinical efficacy include anti-a4 integrin (natalizumab), anti-TNFa (CDP571), and anti-C5 (eculizumab), with the latter antibody containing both IgG2 and IgG4 sequences [9] [10] [11] .
IgG4 is a structurally dynamic antibody
Significant insights into the structural properties of IgG4 have been furnished by analysis and modification of specific residues in the constant region. IgG4 shares more than 95% sequence homology in the constant domain regions with the remaining three IgG isotype heavy chains. The differences between IgG1 and IgG4 for binding to C1q and Fc receptors have been localized to a few amino acid differences in the CH2 domain, notably P331S for C1q binding [15, 16] and L234F and P331S for Fc receptor binding [17] . The most conspicuous differences in sequences among the four IgG isotypes are in the hinge regions with varying lengths of proline-rich amino acid sequences containing a core hinge CXXC element (P, proline; S, serine; L, leucine; F, phenylalanine; C, cysteine; X, any amino acid) that can participate in the formation of covalent disulfide bridges between the two heavy chains. A distinctive feature of IgG4 antibodies is the increased susceptibility of the two core hinge interheavy chain disulfide bonds to chemical reduction [18] . The amino acid sequence of the core IgG4 hinge is CPSC, with the cysteine pair occupying positions 226 and 229 under the EU numbering system [19] . In contrast, the core IgG1 hinge, CPPC, which is less susceptible to reduction, has a proline present at position 228 rather than serine. The S228 in IgG4 results in a more flexible hinge enabling the formation of an intrachain cyclized disulfide [20] and leads to the appearance of 'half-antibodies', which contain noncovalently linked heavy chains as determined by analysis of IgG4 antibodies under denaturing conditions [21, 22, 23 ] . Angal et al. [23 ] made the observation that the appearance of half-antibodies could be greatly reduced by changing the S228 of the IgG4 to proline as in IgG1. A number of therapeutic IgG4 antibodies have a hinge-engineered region including the S228P alteration (see Table 2 ).
Over the last decade, ground-breaking work from Aalberse et al. [24 ] has elucidated the basis of the half-antibody exchange reaction, also referred to as Fab arm exchange, unique to IgG4 antibodies. This work 120 Systemic disorders with rheumatic manifestations
Key points
IgG4 antibodies undergo 'half-antibody exchange' in vivo, resulting in recombined antibodies comprising two different binding specificities. IgG4 does not activate complement pathways and has reduced effector function relative to other IgG subtypes. IgG4 production is driven in part by Th2 cytokines.
The role of IgG4 antibodies in the pathogenesis of IgG4-RSD remains unclear at this time. has shown that the increased susceptibility of the native IgG4 hinge disulfide bonds to reduction allows the heavy chains to separate and randomly re-associate to produce a mixed population of IgG4 molecules with randomized heavy-chain and light-chain pairs (Fig. 1) . One pivotal study demonstrated that the separation of the IgG4 heavy chains is also facilitated by the weaker interaction between the CH3 domains of the IgG4 subclass, as
Biology of the IgG4 subtype Nirula et al. 121 AML, acute myeloid leukemia; Ig, immunoglobulin; IGF1-R, Insulin-like growth factor-1 receptor; IL, interleukin; TNF-a, tumor necrosis factor-alpha; UCB, union chimique belge. substituting the IgG1 CH3 domain into an IgG4 prevents the exchange process [25 ] . Our pharmacokinetic results in animal models and in human patients with Natalizumab, a commercially approved anti-a4 integrin IgG4 antibody, shows that this exchange reaction takes several days to reach equilibrium and that the kinetics of the exchange is dependent on the individual's endogenous IgG4 levels (Biogen Idec and Elan, unpublished data).
The result of half-antibody exchange is that most IgG4 molecules in circulation will consist of two different Fab arms rendering them 'bi-specific' and functionally monovalent for a given antigen. Consequently, IgG4 antibodies in the circulation cannot form immune complexes with antigen, as would occur with the other IgG subclasses. The formation of immune complexes activates the complement pathway and immune effector cell function and given their already low affinity for C1q and Fc receptors, IgG4 antibodies have low theoretical potential for immune activation. Moreover, to the degree IgG4 antibodies can displace the binding of those IgG1 or IgE antibodies with related specificities, they could counteract the inflammatory properties of these other subclasses. This counter-inflammatory property may provide an explanation for another observation made by Aalberse et al. [24 ] that IgG4 antibodies commonly arise after long-term exposure to an antigen, such as an allergen, thereby reducing the degree of chronic inflammation to environmental stimuli.
Control of IgG4 production
Exposure of appropriately activated B cells to a particular cytokine milieu will direct B cells to differentiate into antibody-producing plasma cells that secrete antibody of a specific isotype. All B cells express IgM until signals are provided to initiate isotype switching to produce an IgA, IgE or an IgG subtype [1]. The driving force behind IgG4 production is not fully understood, especially in light of the fact that most cytokines found to be involved in promoting or enhancing IgG4 production have similar effects on IgE production. What shifts the balance between IgG4 and IgE is not clear, although there are some hints emerging. Based on data from a variety of in-vitro assays and analyses of individuals with specific allergies and parasitic infections, the drive to IgG4 production appears to be dependent upon the stimulating antigen and the immediate microenvironment.
In the context of an allergic response, generation of IgEproducing plasma cells is largely dependent on interleukin-4 (IL-4), a Th2 cytokine. Other cytokines such as IL-5, IL-6, IL-7, IL-9, and IL-13 have also been described to be involved in triggering IgE production [26] . These same cytokines, as well as IL-10 and IL-12 [27, 28] , promote and enhance IgG4 production. It is hypothesized that initial low-level exposure to an allergen results in an IgE immune response that produces long-lived plasma cells, but without a germinal center reaction and development of B cell memory. In one model, it is proposed that chronic exposure to an allergen provides a strong stimulus to generate a germinal center reaction wherein exposure to IL-4 and other cytokines stimulate a switch to IgG4, and wherein IgE-expressing B cells do not survive [29] .
In-vitro data in which human peripheral blood mononuclear cells were stimulated with IL-4 or IL-13 showed that addition of IL-10 into the culture media resulted in a preferential production of IgG4 over IgE [27] . Data also suggest that IL-10-producing T-regulatory cells may suppress IgE production, thus leading to a 'modified Th2' response, which results in allergen-specific IgG4producing plasma cells [30] . More recently, it was described that IL-21, a pleiotropic cytokine produced by activated T cells, can either activate or inhibit IgE and IgG4 production depending on the B cell activating conditions. Interestingly, IL-21 appears to stimulate the secretion of IgG4 protein without causing IgG4 switch, suggesting that IL-21 promotes activation or expansion of B cells already committed to IgG4 production [31 ] .
Little has been done to determine whether B cells with a particular phenotype are biased toward IgG4 production. A single report examined IgG4 production in vitro from two distinct B cell subsets [32] . The expression of CD148, a receptor-type protein tyrosine phosphatase, was examined on human splenic B cells with CD148 þ B cells exhibiting characteristics of memory B cells. In invitro cultures of CD148 þ and CD148 À human B cells with various stimuli, IgG4 was produced predominantly from CD148 À naive B cells.
Implications of IgG4 structure, function, and biology for a specific role in IgG4-related systemic disease
As discussed in detail elsewhere in this issue, a seemingly disparate group of inflammatory diseases (including sclerosing forms of sialadenitis, pancreatitis, and cholangitis, as well as aortitis, thyroiditis, and retroperitoneal fibrosis) appear to be unified by similar histopathologic findings and elevated IgG4 levels, and have been described collectively as IgG4-RSD [24 ,33-35] . It is unclear whether IgG4 directly mediates the disease process or reflects a protective response induced by anti-inflammatory cytokines, and could regardless represent an important biomarker. These are critical questions being raised in ongoing research on IgG4-associated diseases.
One disease entity where the pathologic role of IgG4 antibodies is well understood is the blistering skin disease pemphigus [36] . Here, an IgG4 antibody to the epithelial antigen desmoglein causes direct disruption of the epithelial layer and blister formation without antibody-mediated effector function or complement activation. Given the properties of IgG4 described herein, proposal of a direct pathologic role for IgG4 would not generally encompass a significant role for effector cells or any role for complement. It must be noted that in some settings, the residual binding of IgG4 mAbs to Fc receptors can lead to effector cell activation [37 ] , and Fc variants with further ablation of effector function have actually been engineered into IgG therapeutic antibodies [38, 39] . The timing of half-antibody exchange of IgG4 molecules in vivo is relevant to proposed pathophysiology. If antibody-mediated crosslinking and activation of effector function are required for disease, these events would likely occur prior to exchange of IgG4 arms and conversion of the antibody from its original bivalent form.
In Th2 immune responses elevated levels of IgG4 can be associated with increases in IgE and IgG1 antibodies, which have more potent inflammatory properties. Increased IgE levels have indeed been noted in some reports of IgG4-RSD [40 ] , although levels of IgE reportedly show poorer correlation with these diseases than IgG4 (Arezou Khosroshahi & John Stone, personal communication). The characteristic biopsy finding of the diseases is a lymphoplasmacytic infiltrate with IgG4staining plasma cells and/or CD20 positive cells [40 ] . Given case reports of good therapeutic responses to the anti-CD20 B-cell depleting antibody Rituximab (Genentech, South San Francisco, California, USA) in IgG4-RSD [41 ] further work is required to characterize the relative importance of CD20 positive cells and/or plasma cells in production of IgG4, as well as the specificities of IgG4 antibodies produced.
Conclusion
IgG4 is a unique antibody from the standpoint of structure, function, and immunologic regulation. The role of Th2 cytokines in IgG4 biology provides functional linkage to allergic responses. IgG4-RSD represents a newly described category of diseases with a potential role for IgG4 antibodies. The lack of effector function of IgG4 and the phenomenon of half-antibody exchange raise complex questions as to whether antibodies of this subtype are pathogenic or alternatively, mediate a counter-regulatory response to ongoing immunologic disease. Increased understanding of the precise role of IgG4 in these clinical syndromes will likely be pivotal for elucidation of the underlying pathophysiology.
